Trial Profile

Phase 1 Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients With Unresectable Stage III or Stage IV Cutaneous Melanoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IFx 2.0 (Primary) ; IFx 2.0 (Primary)
Indications Malignant melanoma
Focus Adverse reactions; First in man
Sponsors Morphogenesis; TuHURA Biosciences

Most Recent Events

05 Aug 2022 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Primary endpoint (Feasibility; defined as the ability to treat at least five of the six patients enrolled without dose-limiting) has been met according to the results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com